The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.
Drawings
Claims10
A method of enhancing antiviral activity in a subject infected by a virus, comprising administering an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group:
i) choline;
ii) phosphocholine;
iii) cytidine diphosphate-choline (CDP-choline);
iv) phosphorylcholine;
and
v) phosphatidylcholine.
3 more elements
A method for treating a subject infected by a viral disease, comprising administrating an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group:
i) choline;
ii) phosphocholine;
iii) cytidine diphosphate-choline (CDP-choline);
iv) phosphorylcholine;
and
v) phosphatidylcholine.
3 more elements
A method of enhancing antiviral activity in a subject, comprising administering an antiviral composition to the subject infected by a virus, wherein the virus is any one selected from the group consisting of rhinovirus type 2, rhinovirus type 3, rhinovirus type 5, coxsackievirus type A and coxsackievirus type B, and the composition comprises cytidine triphosphate (CTP).
15/389,248Filed 22 Dec 2016 · continuation in part
Priority
KR 10-2014-007836425 Jun 2014
Published
US 2017/0173065 A122 Jun 2017
Granted
9 Oct 2018
Term ends
25 Jun 2035Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
Animal feeding-stuffs: from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
Life of this patent
About 8 years 8 months of term left · ends 25 Jun 2035 (estimated)
Priority, Korea25 Jun 2014
Filed22 Dec 2016
Granted9 Oct 2018
Today12 Oct 2026
Term ends25 Jun 2035
Priority, Korea25 Jun 2014
Granted9 Oct 2018
Term ends25 Jun 2035
Priority claimedKR 10-2014-0078364
Application filedUS 15/389,248
Assigned to Korea Research Institute of Bioscience and Biotechnologyassignment of assignor's interest
PublishedUS 2017/0173065 A1
GrantedUS 10,092,587 B2
TodayWithin its term
Term endsEstimated
Description6,922 words
Summary869 words
#The present invention relates to a composition for inhibiting viral proliferation, comprising at least one substance involved in phosphatidylcholine synthesis pathway, a pharmaceutical composition for preventing or treating viral diseases comprising the same, and a health functional food composition, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.
#Picornavirus is a positive single-stranded RNA virus with 7.2 Kb to 8.5 Kb, in which an RNA genome is only 7500 nt long. In addition, the virus is a very small globular non-enveloped virus with a size of approximately 22 nm to 30 nm, and is the oldest known virus. Rhinovirus, enterovirus, cardiovirus, aphthovirus, hepatovirus, etc. belong to picornavirus.
#At least 50% of cold-inducing pathogenic viruses are rhinovirus. However, therapeutic agents against rhinovirus infection have not yet been developed. As drugs that inhibit rhinoviruses, tremacamra (Turner R B et al., 1999, JAMA 281:1797-1804) which is a drug inhibiting rhinoviruses to be bound to ICAM-1, a receptor, in the form of sICAM-1, and a drug (Wang, Q M, 2001. Prog. drug Res. 229-253; Chen D H et al., 2003. Bioorg Med Chem Lett 13:3531-3536.; Dragovich P S et al., 2002. J Med Chem 45:1607-1623) which has a function to inhibit rhinovirus (HRV) 3C protease have been reported.
Brief description of the drawings9 figures
#FIG. 1 shows a series of schematic illustration in which human rhinovirus induces host cell necrosis so that progeny virus is released therefrom to induce a cold.
#FIG. 2 shows an action mechanism of substances involved in phosphatidylcholine synthesis pathway of the present invention.
#FIG. 3 shows an effect of inhibiting proliferation of rhinovirus type 2 according to the concentration of substances involved in the phosphatidylcholine synthesis pathway.
Detailed description5,847 words
#In one aspect for achieving the above objects, the present invention provides an antiviral composition comprising at least one substance involved in phosphatidylcholine synthesis pathway.
#The substance involved in the phosphatidylcholine synthesis pathway refers to choline, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, or phosphatidylcholine.
#Choline is changed to phosphocholine by choline kinase under the influence of adenosine triphosphate (ATP). Meanwhile, cytidine, a type of nucleoside, is changed to cytidine triphosphate (CTP) by phosphorylation. CDP-choline is formed when cytidine triphosphate is added to phosphocholine (A. L.Henneberry and three others, 2001. Mole. Bioliology of the Cell 12:511-520p). Phosphatidylcholine is formed when diacylglycerol is added to CDP-choline.